Tumor profiling information Caris Life Sciences provides in its reports isn't backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
Caris: A Big Player in ProfilingAccording to information posted on its website, Caris has profiled the tumors of more than 60,000 cancer patients from 59 countries since 2006; ordered by 6,000 oncologists. The company says it has over 600 employees and operates four laboratories in three metropolitan areas: Dallas, Boston and Phoenix.
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
Zydelig is indicated for patients with relapsed chronic lymphocytic leukemia in combination with rituximab for whom rituximab alone would be considered appropriate therapy; as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma; and for small lymphocytic lymphoma patients who have received at least two prior systemic therapies.
The Cancer Letter recently published information regarding proton therapy facilities in the U.S., highlighting a contention that 85 percent of patients treated with protons have prostate cancer, the logical implication of which would be that this important resource is utilized minimally for other cancers. In this response, we wish to correct this erroneous impression and also wish to highlight the direction that this technology is moving in.
The Oregon Health & Science University Knight Cancer Institute moved one step closer to meeting a spectacular fundraising goal.
The Patient-Centered Outcomes Research Institute approved $54.8 million for 33 clinical effectiveness projects.
The surgeon general issued a call to action this week, addressing the rising epidemic of skin cancer in the U.S. and around the world.
FDA announced two plans to resolve a cluster of impediments to personalized cancer care:
Ethicon, the Johnson & Johnson subsidiary that manufactures nearly three-quarters of laparoscopic power morcellators on the market, has requested a withdrawal of the controversial devices.
